Mumbai, Maharashtra, India, February 2025 – Celagenex LLC has announced the appointment of Pradeep Patni as the Chief Executive Officer – Branded Domestic Formulation Business. With an extensive career spanning leadership roles at Pfizer, Janssen Cilag, Abbott India, Micro Labs, Akumentis, and Wanbury Limited, Patni brings deep expertise in driving pharmaceutical growth, innovation, and operational excellence.
In his new role, Pradeep Patni will report directly to the Board of Directors led by Dr. Rajaram Samant, Founder of Celagenex LLC. His strategic leadership will be instrumental in expanding the company’s branded domestic formulation business, fostering innovation, and enhancing market competitiveness.
Before joining Celagenex LLC, Pradeep Patni served as Chief Executive Officer, Indian Formulation at Wanbury Limited, where he played a pivotal role in business expansion and operational improvements.
Previously, he was Chief Executive Officer at Akumentis, leading business transformation initiatives and reinforcing the company’s market presence in the domestic pharmaceutical industry.
As Executive Vice President at Micro Labs Ltd., he contributed significantly to enhancing regulatory compliance, product innovation, and sales growth.
Earlier, Patni held leadership positions at Abbott India, Pfizer, and Janssen Cilag, where he successfully managed business units in hospital anti-infectives, cardiovascular/metabolic drugs, oncology, ophthalmology, and specialty pharmaceuticals. His diverse experience across sales, marketing, and business strategy makes him a valuable addition to Celagenex LLC’s executive leadership team.
About Celagenex LLC
Celagenex LLC is a leading biotechnology company specializing in cutting-edge cellular metabolism regulation technology. The company has developed a unique technology platform that combines clinically proven biological metabolites and bioavailability enhancers to drive youthful, energetic, and healthy living.
Celagenex has a strong intellectual property portfolio with thirteen issued or filed patents globally, and the company continues to conduct extensive clinical research to validate its discoveries. Its mission is to ease the global healthcare burden through innovative pharmaceutical solutions.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
